Xeloda News and Research

RSS
Xeloda is a drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite. Also called capecitabine.
FDA grants accelerated approval for GlaxoSmithKline's TYKERB

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Combination therapy improves overall survival in women with advanced breast cancer

Combination therapy improves overall survival in women with advanced breast cancer

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Array Biopharma reports Q4 and full year 2009 financials

Array Biopharma reports Q4 and full year 2009 financials

Mylan confirms first-to-file patent challenge relating to Xeloda

Mylan confirms first-to-file patent challenge relating to Xeloda

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

Combo therapy reduces size of brain tumours

Combo therapy reduces size of brain tumours

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

Xeloda (capecitabine) better all round for cancer patients

Xeloda (capecitabine) better all round for cancer patients

ADVENTRX announces positive data from multidrug therapy with cofactor

ADVENTRX announces positive data from multidrug therapy with cofactor

Tykerb (lapatinib) - new anti-cancer treatment approved

Tykerb (lapatinib) - new anti-cancer treatment approved

A pill a day gives renewed hope for breast cancer victims

A pill a day gives renewed hope for breast cancer victims

GSK seeks regulatory approval in U.S., Europe for Tykerb

GSK seeks regulatory approval in U.S., Europe for Tykerb

New data show Enzastaurin's activity across multiple cancer cell lines

New data show Enzastaurin's activity across multiple cancer cell lines

FDA approves Xeloda (capecitabine) oral chemotherapy

FDA approves Xeloda (capecitabine) oral chemotherapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.